Market Research Reports, Inc.

Newer Therapies Will Steer Type 2 Diabetes Market in South-East Asia to $2.7 Billion by 2022; Finds New Report

Market Research Reports, Inc. has announced the addition of “Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth” research report to their website www.MarketResearchReports.com

 

Lewes, DE -- (SBWIRE) -- 09/14/2016 -- The South-East Asian Type 2 Diabetes Mellitus (T2DM) market, which includes South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia, will rise from $1.7 billion in 2015 to $2.7 billion by 2022, at a compound annual growth rate of 7.1%, according to research.

The company's latest report states that as well as the rapidly expanding prevalence population in South-East Asia, market growth will be driven by the increased uptake of recently approved and emerging branded T2DM therapeutics, in favor of lower-cost generic products.

According to Senior Analyst, explains: "Unmet needs relating to patient convenience and ease of use will be addressed significantly over the forecast period. Higher levels of innovation are apparent in the early-stage pipeline, which may lead to considerable improvements beyond the existing range of products, in terms of safety and efficacy in the long term.

"In terms of recently approved therapeutics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors have already achieved strong market uptake and are all expected to increase their market shares over the forecast period. In comparison with many previously marketed therapies, these new products provide improved weight control and lowered hypoglycemia risk."

In terms of late-stage pipeline products with the potential to change the treatment paradigm, six candidates stand out as offering superior safety, efficacy, and patient compliance. These are Novo Nordisk's NN-9535 (semaglutide subcutaneous formulation) and OG-217SC (semaglutide oral formulation) and Eli Lilly's Trulicity (dulaglutide), which are GLP-1 receptor agonists; Merck's ertugliflozin and Theracos's bexagliflozin, which are SGLT-2 inhibitors; and Merck's omarigliptin, which is a DPP-4 inhibitor.

Of these products, Publisher believes that OG-217SC, being a first-to-market oral formulation in the GLP-1 agonist class of drug, has the most potential to change the treatment paradigm due to its improved administration route compared to other drugs in the same class.

Senior Analyst continues: "Although increased uptake of branded drugs is expected, metformin - a low-cost generic drug - will maintain its pivotal role in the T2DM treatment algorithm in South-East Asia. Due to its well-characterized safety and efficacy profiles, wide availability and low cost, metformin will continue to be prescribed as the first-line pharmacotherapy and also remain the favored option for use in combination therapies."

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth report provides analysis of the Type 2 Diabetes Mellitus market across South-East Asia, which includes, South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia. It includes annualized market data from 2015 and forecast to 2022.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher's team of industry experts.

For more information Visit at: http://www.marketresearchreports.com/gbi-research/type-2-diabetes-mellitus-therapeutics-south-east-asia-markets-2022-increasing-usage

Find all Therapeutic Reports at - http://www.marketresearchreports.com/therapeutic

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions